Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CXCR2 | P25025 | 14/20 | 0.64 |
| ▸ | CXCR1 | P25024 | 6/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850672 | 0.86 | CXCR2 (0.84) | MAPTCXCR2CXCR1 | |
| SCHEMBL5847572 | 0.86 | MAPT (0.63) | MAPTCXCR2CXCR1TP53KDM4E | |
| SCHEMBL5846736 | 0.83 | MAPT (0.70) | MAPTCXCR2CXCR1TP53KDM4E | |
| SCHEMBL5846313 | 0.82 | MAPT (0.78) | MAPTCXCR2CXCR1TP53KDM4E | |
| SCHEMBL5846252 | 0.81 | MAPT (0.67) | MAPTCXCR2CXCR1TP53KDM4E | |
| SCHEMBL5845444 | 0.78 | CXCR2 (1.00) | MAPTCXCR2CXCR1 | |
| SCHEMBL5845554 | 0.78 | MAPT (0.62) | MAPTCXCR2CXCR1TP53KDM4E | |
| SCHEMBL5846271 | 0.76 | CXCR2 (1.00) | MAPTCXCR2CXCR1 | |
| SCHEMBL5846068 | 0.73 | CXCR2 (1.00) | MAPTCXCR2CXCR1 | |
| SCHEMBL5846095 | 0.72 | CXCR2 (0.71) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151112-B1 | Pharmaceutical uses and synthesis of nicotinamides | UCB SA (GB) | 2006-12-19 | — | — | US | disclosed |
| US-6777432-B1 | TREATING A SUBJECT HAVING AN INFLAMMATORY DISORDER ALLEVIATED BY THE INHIBITION OF GRO- ALPHA CYTOKINES | DARWIN MOLECULAR CORPORATION | 2004-08-17 | — | — | US | disclosed |